NT-503 ECT: Phase II started

Neurotech began a double-blind, U.S. and Israeli Phase II trial to compare a single NT-503 ECT implant vs. IV Eylea every 8 weeks in about 150 patients who have been treated with >=3 anti-VEGF injecti...